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Adults and children with acute myeloid leukemia (AML) who present with a high initial white blood cell count (WBC) have poor outcomes, and a consistent association with induction death has been observed when the initial WBC is ≥ 100×10 9 /L. (1) However, rates of induction death have varied between trials.(2, 3) Furthermore, major advances in supportive care have been incorporated into routine clinical care such as prompt transfusion of platelets, leukapheresis, hydroxyurea, urate oxidase and hemodialysis. With these advances in supportive care, it is unclear whether poor outcomes with hyperleukocytosis in pediatric AML continue to be problematic.
The Children's Oncology Group (COG) adopted a modified AML Medical
Research Council backbone and accrued patients to trials AAML03P1 and AAML0531.
In this study, we analyzed risk factors for, and outcomes associated with, hyperleukocytosis for children and adolescents with AML.
This report used data collected from AAML03P1(4) and AAML0531.(5) Both studies were approved by each institutional review board and all parents/participants provided informed consent. Common eligibility were ≥ 1 month to ≤ 21 years with de novo AML, and infants aged <1 month with progressive disease and isolated chloromas.
Hydroxyurea was excluded in both. Induction I consisted of cytarabine 100 mg/m 2 /dose intravenous (IV) every 12 h on days 1-10; daunorubicin 50 mg/m 2 /dose IV on days 1,3 and 5; and etoposide 100 mg/m 2 /dose IV on days 1-5. All patients received gemtuzumab (GMTZ) on AAML03P1 whereas administration was randomized on AAML0531 (3 mg/m 2 /dose once on day 6). Uniform guidelines for supportive care were provided. It was recommended that before initiation of chemotherapy, the best possible control of coagulopathy, metabolic derangement, and institution of treatment for fever and/or infection be established. Specific management for hyperleukocytosis consisted of caution with packed red blood cell transfusions and liberal use of platelets as clinically indicated. Both studies suggested allopurinol while AAML031 suggested consideration of rasburicase.
Hyperleukocytosis was defined as an initial WBC count ≥ 100×10 9 /L. All nonhematologic ≥ grade 3 toxicities were obtained prospectively by clinical research associates of participating institutions and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. We did not describe outcomes by GMTZ administration as the outcomes on AAML0531 remain blinded at this time.
We examined the following potential predictors of initial WBC ≥1 00×10 9 /L: age, race, ethnicity, body mass index (BMI) category at diagnosis, FAB AML classification, and cytogenetics. BMI (>2 years) or weight-for-length (1-≤2 years) were used to delineate underweight as < 10th percentile, overweight as > 95th percentile, and normal weight as > 10th to < 95th percentile. (6) We also determined whether patients underwent leukapheresis using data from the Pediatric Health Information System (PHIS), which is an administrative database that includes inpatient data from 43 tertiary children's hospitals. Data from COG and PHIS were merged using a probabilistic merge based on ICD9 diagnosis code, treatment center, and date of birth.
Leukapheresis was defined by a leukapheresis procedure code (9972).
To determine predictors of hyperleukocytosis, univariate and multivariable logistic regression analyses were performed. Associations between toxicities and initial WBC groups were compared using chi-square/Fisher's exact test. The Mann-Whitney test was used to determine differences in medians for continuous variables. All statistical analysis was performed using the SAS statistical program (SAS-PC, version 9.2; SAS Institute, Inc., Cary, NC). All tests of significance were two-sided.
A total of 1,364 children with de novo AML were included in the study; 256 (18.8%, 95% CI 16.7-20.9%) had an initial WBC ≥ 100×10 9 /L. Characteristics are illustrated by the presence or absence of initial hyperleukocytosis (Table 1) .
Multivariable regression analysis showed that age 1 year or less, FAB M1, M4, and M5, inv(16) and FLT3-ITD+ were independently associated with an increased risk of hyperleukocytosis (Appendix 1).
The prevalence of ≥ grade 3 metabolic, pulmonary, and CNS toxicities by initial WBC count are presented in Table 2 (7 children excluded due to lack of, or conflicting data We found that almost 20% of children with de novo AML had hyperleukocytosis at presentation, and that patients at higher risk were infants (≤ 1 year) and those with FAB M1, M4, and M5, inv(16) and FLT3-ITD+. Tumor lysis syndrome was uncommon and hyperleukocytosis was not associated with acute renal failure. However, hyperleukocytosis continues to be associated with pulmonary toxicities in terms of hypoxia and pulmonary hemorrhage as well as CNS ischemia/hemorrhage, with increasing risk in those with higher initial WBC counts.
Our report suggests that pulmonary and CNS injuries are still the major issues associated with hyperleukocytosis in spite of contemporary supportive care. Our report also suggests that leukapheresis does not reduce induction mortality.
We conclude that outcomes remain poor in children with extremely high initial WBC in spite of current supportive care available at institutions. Future supportive care DOI: 10.3324/haematol.2012.065490 trials focused on reducing pulmonary and CNS toxicities should be a priority for children with AML.
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